TICKERNERD
Menu
ABBVABBVHealthcare · Drug Manufacturers - General

ABBV Stock Forecast: AbbVie, Inc. Price Predictions for 2026-2027

Last close, 7 Oct 2026
$271
+1.75% on the day

The 30 Wall Street analysts covering AbbVie, Inc. hold a median 12-month price target of $285 — +5.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 6 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$471.3B
Ticker Nerd rank
96 / 100
Median analyst target
$285
Analysts covering
30
Revenue$17.0B+10.2% y/y
Operating income$6.7B
Net income$3.6B
Free cash flow$3.1B
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.7%
1M
+5.8%
YTD
+21.5%
1Y
+20.1%
From 52W high
0.0%
From 52W low
+38.5%
$196
$271
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ABBV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores AbbVie, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
96 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
99
Accruals
90
Momentum
89
Value
87
Quality
86
Growth
80
Revisions
71
Issuance
61
Size
0

Volatility (99): The share price has been relatively steady.

Issuance (61): The company has been issuing shares or taking on financing, diluting existing holders.

Size (0): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ABBV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ABBV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$200$250$300Jan 26Apr 26Jul 26Oct 26ABBVHigh $328Median $285Low $200

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says30 analysts
24 Buy5 Hold1 Sell
Low $200Median $285High $328

The green dot is the last close — the median target sits +5.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
10 Sept 2026HSBCMaintainsBuy$300 → $315
20 Aug 2026Piper SandlerMaintainsOverweight$298 → $303
20 Aug 2026Piper SandlerMaintainsOverweight—
17 Aug 2026Wells FargoMaintainsOverweight$295 → $300
17 Aug 2026Wells FargoMaintainsOverweight—
13 Aug 2026Wolfe ResearchUpgradeOutperform$300
13 Aug 2026Wolfe ResearchUpgradeOutperform—
11 Aug 2026BNP ParibasMaintainsNeutral$218 → $247
11 Aug 2026BNP ParibasMaintainsNeutral—
10 Aug 2026Evercore ISI GroupMaintainsOutperform$246 → $260
10 Aug 2026Evercore ISI GroupMaintainsOutperform—
6 Aug 2026BerenbergMaintainsBuy—
5 Aug 2026Erste GroupUpgradeBuy—
4 Aug 2026GuggenheimMaintainsBuy—
4 Aug 2026GuggenheimMaintainsBuy$261 → $288
3 Aug 2026Canaccord GenuityMaintainsBuy—
3 Aug 2026Canaccord GenuityMaintainsBuy$282 → $290
3 Aug 2026Cantor FitzgeraldMaintainsOverweight$265 → $285
3 Aug 2026Cantor FitzgeraldMaintainsOverweight—
3 Aug 2026Morgan StanleyMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ABBV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ABBV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, AbbVie, Inc. returned +20.1% against +17.4% for the S&P 500, dividends included.

ABBV vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120Jan 26Apr 26Jul 26Oct 26ABBVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ABBV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−1.7%
Analysts raising
0
Analysts cutting
1
Fundamentals

AbbVie, Inc. (ABBV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
77.4×

Cheaper than 10% of US stocks

Price / sales
7.5×

Cheaper than 18% of US stocks

Price / book
−82.5×

Cheaper than 99% of US stocks

EV / EBITDA
17.4×

Cheaper than 19% of US stocks

Growth & margins
Revenue growth (YoY)
10.2%

Higher than 52% of US stocks

Earnings growth (YoY)
285.2%

Higher than 92% of US stocks

Gross margin
74.7%

Higher than 87% of US stocks

Operating margin
40.0%

Higher than 92% of US stocks

Net margin
9.8%

Higher than 69% of US stocks

Returns & dividend
Return on equity
−129.7%

Higher than 11% of US stocks

Return on assets
10.5%

Higher than 93% of US stocks

Dividend yield
2.5%

Higher than 83% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

AbbVie, Inc. (ABBV) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • AbbVie, Inc. has a market value of $471.3B and an enterprise value of $535.6B.

  • Revenue in the twelve months to 30 June 2026: $64.4B. The latest quarter grew 10.2% year on year.

  • Net income over the same four quarters: $6.3B, a 9.8% net margin.

  • Diluted earnings per share, trailing twelve months: $3.54.

  • Free cash flow in the twelve months to 30 June 2026: $18.2B.

  • AbbVie, Inc. spent $1.5B on share buybacks and $12.0B on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 1.8B.

  • Trailing P/E: 77.4×; forward P/E: 16.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 2.52%, paying out 190% of earnings.

  • AbbVie, Inc. employs 57,000 people — $1.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

ABBV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
ABBVAbbVie, Inc.$471.3B
96
JNJJohnson & Johnson$614.0B
85
MRKMerck & Co., Inc.$352.3B
83
AMGNAmgen, Inc.$217.0B
93
LLYEli Lilly & Co.$1.1T
92
GILDGilead Sciences, Inc.$179.1B
94
PFEPfizer Inc.$156.4B
82

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own AbbVie, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ABBV news & analysis

5 Dividend Stocks With Fortress-Like Coverage and Room for Things to Go Wrong

24/7 Wall Street · 7 Oct 2026neutral

24/7 Wall Street lists five dividend-paying companies with varying degrees of dividend coverage, noting that one only narrowly cleared the bar last quarter. The excerpt does not identify the companies or provide details specific to AbbVie.

Why it matters — The item concerns dividend coverage, a topic relevant to ABBV watchers, but the excerpt gives no AbbVie-specific coverage information.

AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC

PRNewsWire · 7 Oct 2026positive

AbbVie said the FDA granted two Breakthrough Therapy Designations for investigational telisotuzumab adizutecan (Temab-A) in colorectal cancer and non-small cell lung cancer. The company described these as Temab-A’s first such designations.

Why it matters — The designations add to AbbVie’s ADC portfolio, which the company said now includes four Breakthrough Therapy Designations.

HSBC Thinks AbbVie Can Climb to $315. Here's the Bull Case in Plain English.

The Motley Fool · 6 Oct 2026positive

The Motley Fool reports that an analyst sees expanded uses for Rinvoq and Skyrizi supporting a potential AbbVie share price of up to $315. The article presents this bull case as potentially strengthened by further efforts to expand AbbVie’s drug pipeline.

Why it matters — ABBV watchers may follow the drugs’ expanded uses and pipeline efforts as factors in the analyst’s outlook.

AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL

Zacks Investment Research · 6 Oct 2026positive

AbbVie said its epcoritamab plus R-CHOP regimen reduced the risk of progression or death by 51% in frontline diffuse large B-cell lymphoma (DLBCL), meeting the phase III study’s progression-free survival goal.

Why it matters — The phase III PFS result highlights a positive clinical-trial outcome for an AbbVie combination in frontline DLBCL.

Wall Street Analysts See AbbVie (ABBV) as a Buy: Should You Invest?

Zacks Investment Research · 6 Oct 2026positive

Zacks Investment Research reports that Wall Street analysts see AbbVie (ABBV) as a buy. The excerpt notes that investors often consider analyst recommendations and that rating changes are sometimes covered in the media.

Why it matters — ABBV watchers may follow analyst recommendations and rating changes as part of their view of the stock.

FAQ

Frequently asked questions about ABBV stock

What is the ABBV stock price forecast for 2026-2027?

The 30 Wall Street analysts covering AbbVie, Inc. have a median 12-month price target of $285, with estimates ranging from $200 to $328. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ABBV stock a buy right now?

Of the 30 analysts covering AbbVie, Inc., 24 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks AbbVie, Inc. 96 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ABBV?

As at 6 Oct 2026, AbbVie, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).

Will ABBV stock go up?

No one can know that. What the data says: the median 12-month target from 30 analysts implies +5.0% from the last close, and Ticker Nerd's factor model ranks AbbVie, Inc. 96 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ABBV stock forecast for 2030?

No analyst covering AbbVie, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABBV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $200 to $328 over the next 12 months.

How has ABBV stock performed over the past year?

AbbVie, Inc. returned +20.1% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does AbbVie, Inc. do?

AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and commercializes medicines and therapies for complex and serious diseases.

What is the latest news on ABBV?

The most recent item we track (24/7 Wall Street, 7 Oct 2026): "5 Dividend Stocks With Fortress-Like Coverage and Room for Things to Go Wrong". 24/7 Wall Street lists five dividend-paying companies with varying degrees of dividend coverage, noting that one only narrowly cleared the bar last quarter. The excerpt does not identify the companies or provide details specific to AbbVie.

Company

About AbbVie, Inc.

AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and commercializes medicines and therapies for complex and serious diseases. AbbVie focuses on major therapeutic areas including immunology, oncology, neuroscience, eye care, aesthetics, and virology, serving patients with chronic autoimmune conditions, blood cancers, inflammatory disorders, and other specialized medical needs. The company’s portfolio includes branded prescription medicines and advanced therapies distributed through physicians, wholesalers, specialty pharmacies, healthcare facilities, and other healthcare channels. AbbVie also supports contract manufacturing services for selected biologics and pharmaceutical processes. Headquartered in North Chicago, Illinois, AbbVie operates as a research-driven healthcare business with a broad international footprint and a strong role in specialty medicine markets.

CEO Mr. Robert A. Michael CPA · 57,000 employees · United States · https://www.abbvie.com